Systematic Review Highlights Flibanserin and Bremelanotide as Leading Emerging Therapies for Female HSDD
Background
Hypoactive Sexual Desire Disorder (HSDD) is a prevalent and distressing condition significantly impacting adult women's quality of life and relationships. Current pharmacological treatment options for HSDD remain limited, necessitating a comprehensive evaluation of emerging therapies. Understanding the therapeutic development, efficacy endpoints, and safety profiles of novel agents is crucial to address this unmet clinical need. This review aims to synthesize evidence from registered clinical trials to clarify the landscape of pharmacological interventions for HSDD.
Study Design
Researchers conducted a systematic review following PRISMA 2020 guidelines, searching ClinicalTrials.gov for completed interventional pharmacological trials for HSDD in adult women. Eligibility criteria focused on studies evaluating pharmacological agents. Data were extracted on study design, participant characteristics, investigational agents, efficacy outcomes related to sexual desire and distress, and reported safety outcomes. The findings were synthesized descriptively, without pooled quantitative analysis, to provide an overview of therapeutic development.
Results
The review identified a total of 9 completed pharmacological clinical trials meeting the inclusion criteria. Most were Phase II and Phase III randomized, double-blind, placebo-controlled studies, primarily enrolling premenopausal women with acquired, generalized HSDD. Investigational therapies predominantly targeted central nervous system pathways. Flibanserin and bremelanotide represented the most extensively studied agents among the identified trials. Efficacy outcomes commonly included validated patient-reported measures such as the Female Sexual Function Index desire domain and the Female Sexual Distress Scale. However, endpoint designation and reporting completeness varied across trials. Safety data were inconsistently reported, with adverse events generally reflecting the pharmacological mechanisms of the agents studied.
Flibanserin and bremelanotide were the most frequently investigated pharmacological agents for HSDD in the 9 completed trials reviewed, primarily targeting
CNSpathways.
Key Findings
- A total of 9 completed pharmacological clinical trials for HSDD met the review's inclusion criteria.
- Most identified trials were Phase II and Phase III randomized, double-blind, placebo-controlled studies.
- Trials primarily enrolled premenopausal women with acquired, generalized HSDD.
- Flibanserin and bremelanotide were the most extensively studied investigational agents.
- Efficacy outcomes commonly used included the
Female Sexual Function Indexdesire domain andFemale Sexual Distress Scale.
Why It Matters
This systematic review consolidates the current clinical trial evidence for pharmacological treatments of Hypoactive Sexual Desire Disorder (HSDD), offering a clearer picture for clinicians and patients. Understanding the landscape of emerging therapies, particularly flibanserin and bremelanotide, can inform treatment discussions and future research directions. The identified focus on CNS-targeting agents highlights a key mechanistic approach. The inconsistent safety reporting across trials underscores the need for standardized adverse event collection and reporting in future studies, which is critical for developing robust, usable protocols and ensuring patient safety. This review helps contextualize the efficacy and safety data available for these specific compounds.
hsdd
female-sexual-dysfunction
flibanserin
bremelanotide
systematic-review
clinical-trials